News

The FDA set the Under the Prescription Drug User Fee Act date for June 24, 2022.

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

The androgen receptor inhibitor darolutamide prolonged overall survival compared with placebo in patients with at least 6 comorbidities.

Frontline niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

First-line treatment with olaparib plus abiraterone resulted in a 34% risk reduction of radiographic disease progression or death in patients with metastatic castration-resistant prostate cancer.

A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.

CTCA Phoenix one of just seven Magnet-recognized hospitals in Arizona

Awareness of the e-cigarette epidemic among youth could help drive primary prevention.

Although technology alone can’t solve clinician burnout, it can provide the means for organizations to provide better care while increasing efficiency and alleviating stress.

Tebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.

With nearly two-thirds of the states allowing for medical cannabis use and the legalization of hemp, accessing cannabinoids has become much easier— especially for patients with cancer.

Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.

Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.

An expert discusses the consequences of cisplatin-induced hearing loss and ongoing research efforts to eliminate this associated risk for children receiving the treatment.

A nurse-driven palliative care referral intervention demonstrated preliminary success in increasing the number of patients who received this form of supportive care.

Experts from Roswell Park developed a dosing guide for the prescription of buprenorphine as treatment for chronic pain.

Since the onset of COVID-19, the United States, Brazil, India, and Russia have maintained a status of having the highest incidence of confirmed cases.

An expert with Oregon Health & Science University discusses whether Orca-T graft can fulfill an unmet need in the field of allogeneic stem cell transplantation for myelofibrosis.

The COVID-19 pandemic has affected oncology practice in many ways. What will safe treating look like moving forward?

Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

Frontline treatment with brentuximab vedotin and chemotherapy yielded superior survival outcomes in patients with advanced classical Hodgkin lymphoma.

Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

Although e-cigarettes are often marketed as a “safe alternative,” non-smokers should understand that smoking still poses risks of lung damage, explains an expert with CTCA.

The program is designed to reduce the age-adjusted death rate associated with cancer by at least 50% over the next 25 years.

Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.

Janelle Wagner, RN, OCN, Senior Manager of Patient Navigation Program for Community Sites, highlights some challenges commonly associated with nurse navigation, and how nurses can overcome them.

An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.

An expert from Arizona Oncology discusses the unmet need for agents to address recurrent ovarian cancer and how upifitamab rilsodotin, an antibody-drug conjugate with promising preclinical and clinical data, may play into the treatment paradigm.